Insider trading

Period: 120 months Stock: MDGL Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

41 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

41 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

41 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

41 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
41 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
41 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

41 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
17 Aug 2026
Kelley Shannon T General Counsel
Sold at will
$341.94K 664 at 514.97
5.5%
Not planned
1 Jun 2026
Soergel David Chief Medical Officer
Sold on a plan
$516.56K 1,042 at 495.74
9.4%
Planned (10b5-1)
18 May 2026
Soergel David Chief Medical Officer
Sold at will
$435.42K 844 at 515.90
7.1%
Not planned
6 Mar 2026
Huntsman Carole Chief Commercial Officer
Sold at will
$180.98K 419 at 431.94
3.2%
Not planned
6 Mar 2026
Kelley Shannon T General Counsel
Sold at will
$155.50K 360 at 431.94
2.9%
Not planned
26 Jan 2026
Huntsman Carole Chief Commercial Officer
Sold on a plan 2×
$449.34K 910 at 493.78
9.1%
Planned (10b5-1)
20 Jan 2026
Kelley Shannon T General Counsel
Sold on a plan 2×
$344.17K 692 at 497.36
7.5%
Planned (10b5-1)
21 Nov 2025
Huntsman Carole Chief Commercial Officer
Sold on a plan 11×
$1.08M 1,958 at 553.11
16.3%
Planned (10b5-1)
18 Aug 2025
Kelley Shannon T General Counsel
Sold on a plan 8×
$479.63K 1,304 at 367.81
12.4%
Planned (10b5-1)
5 Mar 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 9×
$4.82M 14,113 at 341.32
79.1%
Sold half or more
3 Mar 2025
Huntsman Carole Chief Commercial Officer
Sold on a plan 9×
$597.84K 1,834 at 325.98
17.6%
Planned (10b5-1)
3 Mar 2025
Kelley Shannon T General Counsel
Sold on a plan
$139.03K 415 at 335.00
5.4%
Planned (10b5-1)
28 Feb 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$418.49K 1,227 at 341.07
24.8%
Not planned
24 Jan 2025
Taub Rebecca Pres., R&D, and CMO
Sold at will
$217.24K 648 at 335.24
0.1%
Not planned
24 Jan 2025
Huntsman Carole Chief Commercial Officer
Sold at will
$116.33K 347 at 335.24
3.2%
Not planned
24 Jan 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$34.53K 103 at 335.24
2.0%
Not planned
17 Jan 2025
Taub Rebecca Pres., R&D, and CMO
Sold at will
$461.79K 1,689 at 273.41
0.4%
Not planned
17 Jan 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$120.85K 442 at 273.41
8.0%
Not planned
17 Jan 2025
Kelley Shannon T General Counsel
Sold at will
$75.73K 277 at 273.41
3.5%
Not planned
21 Nov 2024
Huntsman Carole Chief Commercial Officer
Sold at will
$218.04K 688 at 316.92
6.0%
Not planned
14 Jun 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$532.00K 1,900 at 280.00
25.7%
Not planned
12 Jun 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$570.00K 2,000 at 285.00
26.7%
Not planned
21 May 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$239.67K 1,036 at 231.34
15.9%
Not planned
8 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 6×
$658.26K 2,676 at 245.99
0.6%
Planned (10b5-1)
5 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 6×
$6.69M 27,506 at 243.36
5.7%
Planned (10b5-1)
4 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 8×
$4.50M 18,537 at 242.91
3.9%
Planned (10b5-1)
3 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 5×
$6.83M 27,845 at 245.14
5.7%
Planned (10b5-1)
15 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$477.00K 2,000 at 238.50
26.1%
Not planned
14 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$465.00K 2,000 at 232.50
26.1%
Not planned
13 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$563.50K 2,500 at 225.40
30.6%
Not planned
12 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$283.20K 1,300 at 217.85
18.7%
Not planned
5 Dec 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will
$227.33K 1,000 at 227.33
6.2%
Not planned
4 Dec 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 2×
$393.96K 1,800 at 218.87
10.7%
Not planned
30 Nov 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 3×
$613.73K 3,000 at 204.58
16.7%
Not planned
29 Nov 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 2×
$796.75K 4,000 at 199.19
21.1%
Not planned
1 Mar 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold, plan not stated 4×
$1.37M 5,000 at 274.42
46.9%
28 Feb 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold, plan not stated 2×
$1.36M 5,000 at 272.07
46.9%
3 Jan 2023
Lynch Brian Joseph SVP and General Counsel
Sold, plan not stated 10×
$3.68M 13,000 at 282.92
100%
Sold half or more
23 Dec 2022
Sukhija Remy Chief Commercial Officer
Sold, plan not stated 18×
$8.22M 30,000 at 274.14
100%
Sold half or more
23 Dec 2022
Lynch Brian Joseph SVP and General Counsel
Sold, plan not stated 14×
$1.92M 7,000 at 274.18
100%
Sold half or more
11 Jun 2018
Taub Rebecca Chief Medical Officer, EVP R&D · indirect
Bought
$21.14M 73,526 at 287.46
12.6%
First buy on file
Showing 1–41 of 41.